In 2018, Khan et al. demonstrated the first time within a prospective phase II study of anti-EGFR monoclonal antibodies in patients with RAS wild type mCRC that the combination of longitudinal plasma profiling can be coupled with mathematical modelling of tumor evolution allows individualized quantitative forecasting of relapse, thus impacting on future clinical decisions (69). This evidence concerns the gene EGFR and neoplasm.